Skip to main content
TipRanks
Go Ultimate75% OFF

Gilead Sciences (GILD) AI Stock Analysis

14,046 Followers
GILD

Gilead Sciences

(NASDAQ:GILD)

Select Model
Rating:66Neutral
Price Target:$179.00â–²(6.81% Upside)
Action:reiterated
Date:10/30/26

The score is supported most by strong and resilient cash generation and a very constructive earnings call with raised guidance and broad product momentum. Technicals also show a clear uptrend, though momentum indicators are stretched. Offsetting these positives are weak/volatile reported profitability (TTM losses) and an unattractive/less-informative valuation signal from the negative P/E, alongside noted medium-term headwinds (notably the 2028 Biktarvy pricing impact).

Positive Factors
Strong cash generationExceptionally strong operating and free cash flow provides financial resilience even when reported earnings are weak. This supports continued investment in research and development, funding for launches, debt servicing, and shareholder returns without relying solely on external financing.
Negative Factors
Biktarvy pricing pressureThe planned CMS price reduction creates a material, identifiable pressure on Gilead’s largest HIV product and may also affect other U.S. payer channels. Replacing that revenue will require sustained growth from newer HIV products and other therapeutic areas.

Gilead Sciences Key Performance Indicators (KPIs)

Revenue by TypeAnalyzes income from different sources, highlighting which areas are driving growth and which might be underperforming, crucial for assessing the company's financial health and strategic focus.

$0.00$2.00B$4.00B$6.00B$8.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Product sales are the clear growth engine — steady, upward momentum driven by HIV/PrEP strength and oncology launches that prompted management to raise product/base guidance. ‘Other’ is highly erratic and driven by one‑off items (nonrecurring other revenue, licensing/transactional effects), producing outsized spikes that can misleadingly swing reported results. For investors, prioritize the underlying product trajectory and HIV/PrEP/Trodelvy momentum rather than headline EPS volatility from acquisition accounting and tax distortions; watch cell‑therapy softness and lower COVID sales as potential near‑term offsets to product gains.

Data provided by:The Fly

Gilead Sciences (GILD) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%GILD+34.08%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$207.86B
Dividend Yield
1.94%
Average Volume (3M)
5.95M
Price to Earnings (P/E)
-54.1
Beta (1Y)
0.26
Revenue Growth
6.92%
EPS Growth
-147.65%
Country
US
Employees
17,000
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Gilead Sciences Business Overview & Revenue Model

Company Description

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to a...

How the Company Makes Money

Gilead makes money primarily by selling branded prescription medicines to wholesalers, distributors, pharmacies, hospitals, government purchasers, and other healthcare providers across the U.S. and international markets. Its largest revenue streams a...

Gilead Sciences Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:1.19%|Next Earnings Date:Feb 04, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Gilead reported its strongest base business growth in more than a decade, broad-based product momentum, improved margins, raised revenue and adjusted EPS guidance, significant pipeline progress, and continued diversification across HIV, oncology, inflammation, and cell therapy. These positives outweighed the stated challenges, including the projected $1.5 billion 2028 Biktarvy revenue impact from CMS pricing, cell therapy declines, clinical holds, lower Veklury and HCV sales, and acquisition-related charges.

Positive Updates

Strongest Base Business Growth in More Than a Decade
Third-quarter base business sales rose 16% year-over-year to $8.2 billion, the strongest growth in more than a decade and the highest year-over-year growth since 2015. Growth was driven by Biktarvy, Descovy and Yeztugo in HIV, Trodelvy in metastatic breast cancer, and Livdelzi in PBC. Sequentially, base business sales increased 8%.

Negative Updates

Biktarvy Maximum Fair Price Creates a 2028 Revenue Headwind
CMS set Biktarvy pricing at $2,600 per 30-day supply, an approximate 38% discount from the list price in the Medicare channel. Gilead's preliminary analysis projects an approximately $1.5 billion net impact on Biktarvy revenue in 2028, including Medicare and spillover effects across Medicaid, 340B, and other U.S. payer segments.

Company Guidance

Gilead now expects 2026 base business sales to range between $30.7 billion and $31 billion, total product sales to range between $31 billion and $31.3 billion, HIV sales to grow approximately 12% year-over-year, Yeztugo sales of approximately $1 billion for the full year, cell therapy sales to decline mid-teens percentage year-over-year, Veklury sales of approximately $300 million, acquired IPR&D of approximately $12.9 billion, R&D expenses to increase a mid- to high single-digit percentage on a dollar basis and SG&A expenses to increase by a high single-digit percentage on a dollar basis, an effective tax rate between 220% and 165%, non-GAAP loss per share between $1.20 and $0.85, and, excluding approximately $9.95 per share, non-GAAP diluted EPS of $8.75 to $9.10, raised $0.25 on both ends from illustrative August guidance; for 2028, Gilead expects a total net impact to Biktarvy revenue of approximately $1.5 billion, total HIV revenue to grow compared to 2027, and both total product sales and earnings per share to grow compared to 2027.

Gilead Sciences Financial Statement Overview

Summary

Cash flow is a major strength (Cash Flow Score 84) with very strong operating cash flow and free cash flow even during the TTM net loss, supporting resilience and shareholder returns. This is partially offset by weak and volatile reported profitability (Income Statement Score 42) with a sharp TTM deterioration to operating losses and a sizable net loss. The balance sheet is serviceable (Balance Sheet Score 56) with manageable leverage, but returns on equity turned negative in TTM due to the loss.

Income Statement

42Neutral

Balance Sheet

56Neutral

Cash Flow

84Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue30.99B29.44B28.75B27.12B27.28B27.30B
Gross Profit24.77B23.21B22.50B20.62B21.62B20.70B
EBITDA1.29B13.58B4.43B10.50B8.85B11.33B
Net Income-3.86B8.51B480.00M5.67B4.59B6.22B
Balance Sheet
Total Assets51.41B59.02B58.99B62.13B63.17B67.95B
Cash, Cash Equivalents and Short-Term Investments6.44B9.61B11.57B7.26B6.38B6.52B
Total Debt26.23B24.94B26.71B24.99B25.23B26.70B
Total Liabilities38.45B36.41B39.75B39.38B41.96B46.89B
Stockholders Equity13.04B22.70B19.33B22.83B21.24B21.07B
Cash Flow
Free Cash Flow13.78B9.46B10.30B7.42B8.34B10.80B
Operating Cash Flow14.48B10.02B10.83B8.01B9.07B11.38B
Investing Cash Flow-10.65B-4.79B-3.45B-2.27B-2.47B-3.13B
Financing Cash Flow-4.69B-7.75B-3.43B-5.13B-6.47B-8.88B

Gilead Sciences Technical Analysis

Technical Analysis SentimentPositive
Last Price167.58

Price Trends

50DMA155.35Positive
100DMA145.59Positive
200DMA140.72Positive

Market Momentum

MACD4.30Positive
RSI58.37Neutral
STOCH30.76Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GILD, the sentiment is Positive. The current price of 167.58 is above the 20-day moving average (MA) of 164.84, above the 50-day MA of 155.35, and above the 200-day MA of 140.72, indicating a bullish trend. The MACD of 4.30 indicates Positive momentum. The RSI at 58.37 is Neutral, neither overbought nor oversold. The STOCH value of 30.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GILD.

Gilead Sciences Risk Analysis

Gilead Sciences disclosed 22 risk factors in its most recent earnings report. Gilead Sciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our U.S. manufacturing and R&D investments may not achieve their intended benefits and could adversely affect our business, results of operations and cash flows.Q4, 2025
2.The failure to successfully implement or upgrade enterprise resource planning and other information systems could adversely impact our business and results of operations.Q4, 2023
3.Climate change and related natural disasters, as well as legal, regulatory, or market measures to address climate change, can negatively affect our business and operations.Q4, 2023

Gilead Sciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GILD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NVSNVS72Outperform$295.59B31.0824.24%2.96%1.64%-28.72%
JNJJNJ70Outperform$680.19B43.0119.55%1.87%7.81%-35.95%
BMYBMY66Neutral$128.63B13.9443.88%4.00%4.19%52.55%
PFEPFE66Neutral$164.50B40.864.60%5.96%1.34%-58.96%
GILDGILD66Neutral$207.86B-54.06-21.74%1.94%6.92%-147.65%
MRKMRK64Neutral$356.13B147.395.29%2.35%5.21%-86.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%20%40%60%GILDBMYJNJMRKNVSPFEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GILD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GILDGilead Sciences167.5843.4735.02%
BMYBristol-Myers Squibb Company62.9317.8839.67%
JNJJohnson & Johnson282.5586.9644.46%
MRKMerck & Company144.4650.7854.21%
NVSNovartis AG160.2034.6527.60%
PFEPfizer Inc28.865.0121.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026